

Fenoglide - (40,120 mg; Tablet, Oral)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | Fenofibrate | Innovator | SALIX Pharma |
| Dosage | 40,120 mg; Tablet, Oral | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | Less Than 5 | Tentative Approvals | None |
| Final Approvals | Less Than 5 | Generic Launches | Less Than 5 |
| Indication | Adjunct to diet in hypertriglyceridemia and to reduce elevated LDL-C, total-C, TG, and apo B, and to increase HDL-C, in primary hyperlipidemia and mixed dyslipidemia. Limitation of Use: was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.